Enhanced effector functions due to antibody defucosylation depend on the effector cell Fcγ receptor profile

Journal of Immunology

Volumn 199, Issue 1, 2017, Pages 204-211

  Bruggeman, Christine W ^a   Dekkers, Gillian ^a   Bentlage, Arthur E H ^a   Treffers, Louise W ^a   Nagelkerke, Sietse Q ^a   Lissenberg Thunnissen, Suzanne ^a   Koeleman, Carolien A M ^b   Wuhrer, Manfred ^b   Van Den Berg, Timo K ^a   Rispens, Theo ^a   Vidarsson, Gestur ^a   Kuijpers, Taco W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FC GAMMA RECEPTOR IIIA; FC RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; UNCLASSIFIED DRUG; BLOOD GROUP RHESUS SYSTEM; FCGR3A PROTEIN, HUMAN; FCGR3B PROTEIN, HUMAN; FUCOSE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; PROTEIN BINDING; RHO(D) ANTIGEN;

ANTIBODY DEFUCOSYLATION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; EFFECTOR CELL; FUCOSYLATION; HEMOLYSIS; HUMAN; HUMAN CELL; IMMUNOLOGICAL PARAMETERS; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; NORMAL HUMAN; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURFACE PLASMON RESONANCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BLOOD GROUP RHESUS SYSTEM; CHEMISTRY; GENETICS; GLYCOSYLATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; FUCOSE; GLYCOSYLATION; GPI-LINKED PROTEINS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; MACROPHAGES; PROTEIN BINDING; RECEPTORS, IGG; RH-HR BLOOD-GROUP SYSTEM; SURFACE PLASMON RESONANCE;

EID: 85021112769     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1700116     Document Type: Article

References (45)

1. Niwa, R., A. Natsume, A. Uehara, M. Wakitani, S. Iida, K. Uchida, M. Satoh, and K. Shitara. 2005. IgG subclass-independent improvement of antibodydependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J. Immunol. Methods 306: 151-160.
2. Vidarsson, G., G. Dekkers, and T. Rispens. 2014. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 5: 520.
3. Bruhns, P., B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, and M. Daëron. 2009. Specificity and affinity of human Fcg receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725.
4. Caaveiro, J. M., M. Kiyoshi, and K. Tsumoto. 2015. Structural analysis of Fc/FcgR complexes: a blueprint for antibody design. Immunol. Rev. 268: 201-221.
5. Baković,M. P., M.H. Selman, M. Hoffmann, I. Rudan, H. Campbell, A. M. Deelder, G. Lauc, and M. Wuhrer. 2013. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J. Proteome Res. 12: 821-831.
6. Mizushima, T., H. Yagi, E. Takemoto, M. Shibata-Koyama, Y. Isoda, S. Iida, K.Masuda, M. Satoh, and K. Kato. 2011. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 16: 1071-1080.
7. Ahmed, A. A., J. Giddens, A. Pincetic, J. V. Lomino, J. V. Ravetch, L. X. Wang, and P. J. Bjorkman. 2014. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J. Mol. Biol. 426: 3166-3179.
8. Le, N. P., T. A. Bowden, W. B. Struwe, and M. Crispin. 2016. Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies. Biochim. Biophys. Acta. 1860: 1655-1668.
9. Ferrara, C., S. Grau, C. Jäger, P. Sondermann, P. Brünker, I.Waldhauer, M. Hennig, A. Ruf, A. C. Rufer, M. Stihle, et al. 2011. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. USA 108: 12669-12674.
10. Subedi, G. P., Q. M. Hanson, and A. W. Barb. 2014. Restricted motion of the conserved immunoglobulin G1 N-glycan is essential for efficient FcgRIIIa binding. Structure 22: 1478-1488.
11. Shields, R. L., J. Lai, R. Keck, L. Y. O'Connell, K. Hong, Y. G. Meng, S. H. Weikert, and L. G. Presta. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277: 26733-26740.
12. Okazaki, A., E. Shoji-Hosaka, K. Nakamura, M. Wakitani, K. Uchida, S. Kakita, K. Tsumoto, I. Kumagai, and K. Shitara. 2004. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgRIIIa. J. Mol. Biol. 336: 1239-1249.
13. Subedi, G. P, and A. W. Barb 2016. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc g receptor. MAbs 8: 1512-1524.
14. Kapur, R., I. Kustiawan, A. Vestrheim, C. A. Koeleman, R. Visser, H. K. Einarsdottir, L. Porcelijn, D. Jackson, B. Kumpel, A. M. Deelder, et al. 2014. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood 123: 471-480.
15. Niwa, R., S. Hatanaka, E. Shoji-Hosaka, M. Sakurada, Y. Kobayashi, A. Uehara, H. Yokoi, K. Nakamura, and K. Shitara. 2004. Enhancement of the antibodydependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgRIIIa functional polymorphism. Clin. Cancer Res. 10: 6248-6255.
16. Mori, K., S. Iida, N. Yamane-Ohnuki, Y. Kanda, R. Kuni-Kamochi, R. Nakano, H. Imai-Nishiya, A. Okazaki, T. Shinkawa, A. Natsume, et al. 2007. Nonfucosylated therapeutic antibodies: the next generation of therapeutic antibodies. Cytotechnology 55: 109-114.
17. Peipp, M., J. J. Lammerts van Bueren, T. Schneider-Merck, W. W. Bleeker, M. Dechant, T. Beyer, R. Repp, P. H. van Berkel, T. Vink, J. G. van de Winkel, et al. 2008. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112: 2390-2399.
18. Ackerman, M. E., M. Crispin, X. Yu, K. Baruah, A. W. Boesch, D. J. Harvey, A. S. Dugast, E. L. Heizen, A. Ercan, I. Choi, et al. 2013. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest. 123: 2183-2192.
19. Kapur, R., L. Della Valle, M. Sonneveld, A. Hipgrave Ederveen, R. Visser, P. Ligthart, M. de Haas, M. Wuhrer, C. E. van der Schoot, and G. Vidarsson. 2014. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn.Br. J. Haematol. 166: 936-945.
20. Jefferis, R. 2009. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol. Sci. 30: 356-362.
21. Yamane-Ohnuki, N., and M. Satoh. 2009. Production of therapeutic antibodies with controlled fucosylation. MAbs 1: 230-236.
22. Jefferis, R. 2009. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8: 226-234.
23. Suzuki, E., R. Niwa, S. Saji, M. Muta, M. Hirose, S. Iida, Y. Shiotsu, M. Satoh, K. Shitara, M. Kondo, and M. Toi. 2007. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin. Cancer Res. 13: 1875-1882.
24. Satoh, M., S. Iida, and K. Shitara. 2006. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin. Biol. Ther. 6: 1161-1173.
25. Flores, G., C. Cunningham-Rundles, A. C. Newland, and J. B. Bussel. 1993. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am. J. Hematol. 44: 237-242.
26. Imbach, P., S. Barandun, V. d'Apuzzo, C. Baumgartner, A. Hirt, A. Morell, E. Rossi, M. Schöni, M. Vest, and H. P. Wagner. 1981. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1: 1228-1231.
27. Nimmerjahn, F., and J. V. Ravetch. 2008. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26: 513-533.
28. Provan, D., R. Stasi, A. C. Newland, V. S. Blanchette, P. Bolton-Maggs, J. B. Bussel, B. H. Chong, D. B. Cines, T. B. Gernsheimer, B. Godeau, et al. 2010. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115: 168-186.
29. Schwab, I., and F. Nimmerjahn. 2013. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13: 176-189.
30. Burns, J. C., H. I. Kushner, J. F. Bastian, H. Shike, C. Shimizu, T. Matsubara, and C. L. Turner. 2000. Kawasaki disease: a brief history. Pediatrics 106: E27.
31. Durandy, A., S. V. Kaveri, T. W. Kuijpers, M. Basta, S. Miescher, J. V. Ravetch, and R. Rieben. 2009. Intravenous immunoglobulins - understanding properties and mechanisms. Clin. Exp. Immunol. 158(Suppl. 1): 2-13.
32. Nagelkerke, S. Q., and T. W. Kuijpers. 2015. Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all? Front. Immunol. 5: 674.
33. van der Heijden, J., W. B. Breunis, J. Geissler, M. de Boer, T. K. van den Berg, and T. W. Kuijpers. 2012. Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. J. Immunol. 188: 1318-1324.
34. Tsang-A-Sjoe, M. W., S. Q. Nagelkerke, I. E. Bultink, J. Geissler, M. W. Tanck, C. E. Tacke, J. A. Ellis, W. Zenz, M. Bijl, J. H. Berden, et al. 2016. Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. Rheumatology (Oxford) 55: 939-948.
35. Breunis, W. B., E. van Mirre, J. Geissler, N. Laddach, G. Wolbink, E. van der Schoot, M. de Haas, M. de Boer, D. Roos, and T. W. Kuijpers. 2009. Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. Hum. Mutat. 30: E640-E650.
36. Dohmen, S. E., A. Mulder, O. J. Verhagen, C. Eijsink, M. E. Franke-van Dijk, and C. E. van der Schoot. 2005. Production of recombinant Ig molecules from antigen-selected single B cells and restricted usage of Ig-gene segments by anti-D antibodies. J. Immunol. Methods 298: 9-20.
37. Kruijsen, D., H. K. Einarsdottir, M. A. Schijf, F. E. Coenjaerts, E. C. van der Schoot, G. Vidarsson, and G. M. van Bleek. 2013. Intranasal administration of antibody-bound respiratory syncytial virus particles efficiently primes virusspecific immune responses in mice. J. Virol. 87: 7550-7557.
38. Dekkers, G., R. Plomp, C. A. Koeleman, R. Visser, H. H. von Horsten, V. Sandig, T. Rispens, M. Wuhrer, and G. Vidarsson. 2016. Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans. Sci. Rep. 6: 36964.
39. de Lau, W., N. Barker, T. Y. Low, B. K. Koo, V. S. Li, H. Teunissen, P. Kujala, A. Haegebarth, P. J. Peters, M. van de Wetering, et al. 2011. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 476: 293-297.
40. Schasfoort, R. B., K. C. Andree, N. van der Velde, A. van der Kooi, I. Stojanović, and L. W. Terstappen. 2016. Interpolation method for accurate affinity ranking of arrayed ligand-analyte interactions. Anal. Biochem. 500: 21-23.
41. Nagelkerke, S. Q., G. Dekkers, I. Kustiawan, F. S. van de Bovenkamp, J. Geissler, R. Plomp,M.Wuhrer, G.Vidarsson, T. Rispens, T. K. van den Berg, and T.W. Kuijpers. 2014. Inhibition of FcgR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcgRIIb in human macrophages. Blood 124: 3709-3718.
42. Gong, Q, M. Hazen, B. Marshall, S. Crowell, Q. Ou, A. W. Wong, W. Phung, J. M. Vernes, Y. G. Meng, M. Tejada, D. Andersen, and R. F. Kelley. 2016. Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation. MAbs 8: 1098-1106.
43. van Mirre, E., W. B. Breunis, J. Geissler, C. E. Hack, M. de Boer, D. Roos, and T. W. Kuijpers. 2006. Neutrophil responsiveness to IgG, as determined by fixed ratios of mRNA levels for activating and inhibitory FcgRII (CD32), is stable over time and unaffected by cytokines. Blood 108: 584-590.
44. Duvic, M., L. C. Pinter-Brown, F. M. Foss, L. Sokol, J. L. Jorgensen, P. Challagundla, K. M. Dwyer, X. Zhang, M. R. Kurman, R. Ballerini, et al. 2015. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 125: 1883-1889.
45. Ishida, T., and R. Ueda. 2011. Antibody therapy for adult T-cell leukemialymphoma. Int. J. Hematol. 94: 443-452.